Search

Your search keyword '"Morabito F."' showing total 1,301 results

Search Constraints

Start Over You searched for: Author "Morabito F." Remove constraint Author: "Morabito F."
1,301 results on '"Morabito F."'

Search Results

2. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

6. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

7. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

8. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

10. Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study

11. Mechanical Aspects in the Cells Detachment

12. Testing graph robustness indexes for eeg analysis in alzheimer’s disease diagnosis

13. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

14. Automatic Detection of Critical Epochs in coma-EEG Using Independent Component Analysis and Higher Order Statistics

16. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

17. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

19. P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE

20. P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS

21. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

26. Magnetic Diagnostics For ITER

29. Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial

30. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia

31. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

32. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

33. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

34. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

39. Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19

41. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Catalog

Books, media, physical & digital resources